Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court
You may also be interested in...
Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco
MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.
Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco
MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.
Sun Pharma Managing Director Dilip Shanghvi On Building A U.S. Base: An Interview With PharmAsia News (Part 1 of 2)
With a robust business strategy of strengthening its U.S. operations, India's Sun Pharmaceutical has emerged as the most valued Indian drug company. As stock markets hammered down valuations for other top Indian drug companies like Ranbaxy, Dr. Reddy's and Cipla, analysts have largely held Sun's valuations steady. In a rare interview with PharmAsia News' Indian bureau, Sun Pharmaceutical Chairman and Managing Director Dilip Shanghvi shares his thoughts on the long term goals for the company and speaks out on the tangle that his company is engaged in to acquire Israeli drug maker Taro.